S. Kleban

Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.

N. Kemeny, G. Schwartz, L. Saltz, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.